probabl
first
observ
specif
attach
viru
cell
made
start
twentieth
centuri
cultur
shigella
observ
occasion
clear
spot
lyse
bacteria
lawn
bacteri
growth
solid
agar
medium
call
plaqu
virus
lyse
shigella
name
bacteriophag
use
cosediment
experi
show
attach
viru
host
cell
first
step
infect
attach
occur
viru
mix
bacteria
suscept
viru
earli
studi
show
host
rang
viru
determin
attach
step
centuri
later
begin
understand
detail
increas
number
interact
atom
level
virus
contain
nucleicacid
genom
either
rna
dna
packag
protein
encod
viral
genom
virus
divid
two
main
categori
envelop
virus
lipid
membran
envelop
deriv
host
cell
nonenvelop
virus
lack
membran
virus
differ
famili
caus
associ
diseas
human
tabl
crucial
understand
differ
virus
solv
problem
entri
cell
process
inhibit
review
summar
recent
advanc
understand
viru
entri
mechan
molecular
level
option
therapeut
intervent
process
mode
entri
nonenvelop
envelop
virus
share
main
step
rout
viru
entri
begin
attach
cellsurfac
receptor
end
deliveri
viral
genom
cell
cytoplasm
fig
bind
receptor
protein
carbohydr
lipid
virus
use
two
main
rout
enter
cell
endocyt
nonendocyt
rout
endocyt
rout
usual
transport
clathrinco
vesicl
pit
nonclathrinco
pit
macropinocytosi
caveola
also
virus
induc
intern
endocytosi
exampl
simian
viru
induc
local
actin
polymer
dynamin
recruit
site
fig
nonendocyt
rout
entri
involv
directli
cross
plasma
membran
neutral
ph
fig
virus
use
nonendocyt
rout
also
enter
cell
endocyt
pathway
exampl
human
immunodefici
viru
type
membran
fusion
basic
cellular
process
essenti
phagocytosi
pinocytosi
vesicular
traffick
basic
mode
entri
envelop
virus
use
endocyt
nonendocyt
rout
process
regul
mediat
membran
protein
membran
close
proxim
envelop
nonenvelop
virus
entri
cell
involv
import
conform
chang
viral
entri
protein
hostcel
receptor
induc
low
endosom
ph
occur
either
penetr
nonenvelop
virus
fusion
envelop
virus
entri
host
cell
mani
virus
includ
transport
cytoplasm
nucleoprotein
complex
surfaceexpos
nuclear
local
signal
nucleoprotein
complex
allow
target
entri
nucleu
infect
nondivid
cell
entri
virus
echoviru
measl
viru
ebola
viru
viru
ebv
enhanc
lipid
microdomain
known
lipid
virus
includ
influenza
use
lipid
raft
platform
concentr
suffici
number
viral
molecul
virion
effici
exit
one
cell
entri
anoth
howev
fusion
semliki
forest
viru
sfv
sindbi
viru
sin
liposom
requir
raft
presenc
raft
inhibitori
membran
remain
establish
whether
raft
involv
infecti
cell
entri
sfv
virus
enter
cell
direct
celltocel
contact
use
structur
form
polar
cytoskeleton
adhes
molecul
viral
protein
infect
cell
junction
known
virolog
synaps
direct
celltocel
transmiss
virus
process
exampl
retrovirus
human
tcell
lymphomaleukaemia
viru
type
herpesvirus
herp
simplex
viru
hsv
varicellazost
viru
poxvirus
vaccinia
viru
poorli
understood
mani
case
clear
whether
celltocel
transmiss
rout
involv
membran
fusion
penetr
direct
transfer
viru
cell
junction
effici
rapid
celltocel
transmiss
virus
could
altern
mediat
virion
bud
releas
space
close
appos
interact
cell
celltocel
fusion
celltocel
transmiss
might
protect
virus
action
immun
system
could
import
rout
transmiss
vivo
virus
polioviru
enter
exit
cell
without
cross
membran
process
known
transcytosi
vesicular
transport
one
side
cell
use
multicellular
organ
select
move
materi
usual
macromolecul
cell
two
environ
without
modifi
virus
usurp
mechan
cross
epitheli
cell
barrier
infect
underli
cell
kinet
effici
entri
vari
greatli
virus
differ
famili
virus
within
famili
virus
within
genu
even
isol
speci
virus
adenoassoci
viru
serotyp
sfv
influenza
cross
endosom
membran
rapidli
within
second
effici
entri
much
mean
attach
virus
enter
cell
singl
virion
cross
membran
less
individu
influenza
virion
cross
membran
littl
one
virus
take
one
minut
enter
cell
effici
entri
poor
compar
often
low
ref
kinet
effici
viru
entri
might
relat
viru
structur
seem
best
kinet
effici
entri
observ
virus
use
low
ph
entri
trigger
flatten
structur
sfv
cellbound
sfv
fuse
second
effici
ref
membran
lipid
composit
structur
also
affect
kinet
effici
viru
entri
nonenvelop
envelop
virus
use
energi
metast
state
viral
entri
protein
expos
hydrophob
destabil
hostcel
membran
howev
format
differ
intermedi
lead
format
membran
pore
case
nonenvelop
virus
membran
fusion
pore
case
envelop
virus
fig
often
conform
chang
singl
viru
protein
mediat
membran
fusion
envelop
virus
fuse
plasma
membran
insid
endosom
penetr
entri
nonenvelop
virus
might
resembl
entri
toxin
anthrax
entri
envelop
virus
similar
intracellular
fusion
process
viru
structur
receptor
recognit
viru
evolut
result
sever
receptorrecogn
surfac
structur
frequent
protrus
spike
nm
longer
form
entri
protein
exampl
coronavirus
fig
aav
fig
canyon
exampl
picornavirus
human
rhinoviru
fig
nonenvelop
virus
often
small
stabl
form
crystal
diffract
good
resolut
structur
rel
larg
number
repres
differ
viru
famili
group
solv
xray
crystallographi
high
resolut
typic
contrast
structur
whole
envelop
virus
exampl
fig
dengu
publish
solv
resolut
cryoelectron
microscopi
structur
viral
entri
protein
virionassoci
entri
protein
typic
glycosyl
oligom
exampl
homodimer
tickborn
enceph
viru
tbe
e
protein
homotrimer
adenoviru
fibr
influenza
haemagglutinin
ha
fig
attach
protein
virus
exampl
adenovirus
retrovirus
unlik
significantli
interact
wherea
entri
protein
virus
includ
alphavirus
sfv
form
heterodim
protein
interact
extens
form
lattic
interact
protein
fig
entir
capsid
mani
nonenvelop
virus
exampl
picornavirus
human
rhinoviru
fig
form
network
interact
protein
involv
entri
topolog
viral
entri
protein
vari
form
spike
compris
stem
globular
head
fig
exampl
reovirus
adenovirus
orthomyxovirus
paramyxovirus
form
rel
flat
structur
exampl
alphavirus
famili
togavirida
fig
similar
topolog
nonenvelop
reoviru
adenoviru
attach
protein
extend
threedimension
structur
even
though
aminoacid
sequenc
two
protein
share
sequenc
fig
b
similar
structur
togeth
conserv
function
indic
common
ancestor
protein
preclud
converg
evolut
overal
similar
topolog
nonenvelop
reoviru
adenoviru
attach
protein
topolog
envelop
glycoprotein
env
envelop
virus
influenza
respiratori
synciti
viru
rsv
fusion
protein
predict
base
sequenc
similar
homolog
fusion
protein
newcastl
diseas
viru
ndv
notabl
particularli
owe
lack
aminoacid
sequenc
ident
protein
fig
howev
stem
reoviru
adenoviru
attach
protein
stabil
tripl
wherea
stem
influenza
ha
respiratori
synciti
viru
f
protein
stabilis
coiledcoil
indic
virus
differ
ancestor
structur
envelop
flaviviru
e
protein
dengu
envelop
alphaviru
sfv
similar
combin
similar
function
might
indic
exist
common
ancestor
entri
protein
flavivirus
viru
entri
protein
divid
two
class
depend
sever
criteria
includ
mechan
action
whether
entri
protein
cleav
whether
entri
protein
complex
viral
protein
env
contain
coiledcoil
influenza
ha
paramyxoviru
fusion
protein
f
hiv
glycoprotein
design
class
fusion
protein
env
alphavirus
flavivirus
design
class
ii
fusion
viral
entri
protein
divers
aminoacid
sequenc
mani
structur
solv
contain
similar
structur
motif
although
overal
topolog
differ
especi
notabl
nonenvelop
virus
viral
protein
expos
environ
recogn
receptor
molecul
sever
plant
insect
mammalian
virus
contain
basic
core
structur
consist
jellyrol
although
env
structur
solv
seem
might
use
similar
type
structur
motif
nonenvelop
virus
recognit
host
cell
globular
head
bestcharacter
viral
env
mediat
entri
ha
orthomyxoviru
influenza
contain
fig
head
ndv
f
protein
compris
immunoglobulintyp
domain
highli
twist
fragment
two
env
hsv
glycoprotein
receptorbind
domain
friend
murin
leukaemia
viru
frmlv
also
contain
structur
similar
immunoglobulinlik
fold
analysi
limit
number
structur
indic
virus
use
conserv
framework
join
variabl
loop
allow
rapid
adapt
new
receptor
three
xray
crystal
structur
env
receptorbind
domain
unbound
state
solubl
fragment
main
env
flavivirus
dengu
fragment
contain
predominantli
pack
sheet
includ
sixstrand
second
domain
immunoglobulinlik
fold
third
domain
could
import
bind
cellular
receptor
recognit
viru
receptor
host
cell
although
viru
receptor
divers
sequenc
structur
cellular
prefer
molecul
involv
cell
adhes
recognit
revers
multival
aviditydetermin
interact
virus
might
evolv
bind
abund
cellular
receptor
bind
cellular
receptor
rel
low
affin
natur
ligand
high
bind
receptor
characterist
tabl
receptorrecognit
interact
differ
virus
even
differ
isol
viru
vari
significantli
typic
lowaffin
bind
interact
viral
attach
protein
cognat
receptor
involv
small
area
interact
viral
cellular
receptor
lead
conform
chang
entri
protein
exampl
bind
influenza
ha
sialic
highaffin
interact
viru
receptor
involv
larg
area
interact
viral
cellular
receptor
often
involv
larg
conform
chang
exampl
bind
one
coreceptor
polioviru
result
conform
one
except
highaffin
bind
adenoviru
fibr
coxsackievirusadenoviru
receptor
car
involv
signific
conform
chang
fig
highaffin
receptorbind
site
locat
deep
crevic
canyon
viral
protein
picornavirus
contain
loop
caviti
channel
adenoviru
knob
hiv
fig
rather
unusu
hvea
receptorbind
site
glycoprotein
situat
aminotermin
extens
one
edg
glycoprotein
molecul
rather
assembl
mani
part
glycoprotein
sequenc
typic
bind
surfac
bind
pocket
undergo
conform
chang
bind
correl
structur
viral
entri
protein
structur
structur
cellular
receptor
virus
famili
retrovirus
bind
differ
cellular
receptor
cellular
molecul
exampl
sialic
acid
serv
receptor
sever
differ
virus
conform
chang
induc
interact
one
receptor
requir
expos
bind
site
anoth
receptor
exampl
interact
induc
exposur
highaffin
bind
site
coreceptor
typic
case
serv
attach
receptor
ensur
specif
bind
cell
coreceptor
serv
fusion
receptor
induc
conform
chang
lead
exposur
fusogen
sequenc
strain
coreceptor
mediat
attach
fusion
absenc
entri
also
initi
bind
lowaffin
receptor
heparin
sulphat
follow
higher
affin
interact
role
mani
receptor
entri
remain
unresolv
controversi
entri
cell
interact
one
receptor
seem
wide
use
virus
especi
infect
specif
type
cell
vivo
case
specif
cell
receptor
absent
altern
viru
receptor
also
identifi
virus
exampl
galactosyl
sulphat
deriv
sulphatid
support
low
level
infect
cell
line
although
role
altern
receptor
vivo
remain
unknown
although
number
identifi
receptor
human
virus
increas
rapidli
past
two
viru
receptor
remain
uncharacter
xray
crystal
cryoelectron
microscopi
structur
entri
protein
complex
receptor
fig
identif
new
receptor
import
understand
viru
tropism
pathogen
mechan
entri
recent
receptor
sever
acut
respiratori
syndrom
coronaviru
sarscov
angiotensinconvert
enzym
identifi
month
viru
receptorbind
domain
local
aminoacid
residu
sarscov
entri
virusreceptor
function
affect
membran
organ
lipid
raft
intens
studi
determin
possibl
role
viru
although
raft
well
character
role
viru
entri
controversi
studi
entri
illustr
controversi
still
exist
regard
role
raft
viru
entri
togeth
deplet
cholesterol
inhibit
glycosphingolipid
synthesi
decreas
effici
envmedi
membran
fusion
typic
twofold
could
indic
effect
membran
fusion
owe
disrupt
raft
raft
compon
glycosphingolipid
seem
interact
presenc
could
also
indic
raft
involv
howev
recent
data
indic
infect
depend
presenc
raft
propos
cholesterol
modul
entri
independ
mechan
perhap
relat
membran
merg
modul
coreceptor
although
exact
role
raft
receptorexpress
host
cell
controversi
recent
experi
clearli
shown
import
raft
membran
fusion
cluster
suffici
number
influenza
ha
molecul
raft
nm
appear
receptorexpress
envexpress
cell
function
raft
mainli
increas
local
concentr
molecul
involv
entri
glycosphingolipid
might
provid
structur
basi
raft
format
could
also
interact
directli
viral
entri
protein
cellular
receptor
molecul
conform
chang
entri
protein
receptor
recognit
viral
entri
protein
undergo
mark
conform
chang
drive
entri
process
complet
one
hypothesi
entri
protein
mani
virus
includ
polioviru
influenza
hiv
tbe
sfv
metast
highenergi
howev
recent
differenti
scanningcalorimetr
measur
show
unfold
influenza
ha
neutral
ph
endotherm
process
might
indic
metast
highenergi
accord
metastablest
hypothesi
receptor
bind
ph
chang
possibl
possibl
provid
activ
energi
requir
overcom
energi
barrier
viral
entri
protein
reach
stabl
energet
favour
state
energi
transit
state
use
extern
sequenc
intern
part
entri
protein
destabil
membran
structur
transit
viru
entri
protein
subsequ
action
extern
membranedestabil
sequenc
induc
format
membran
pore
membran
fusion
pore
envelop
virus
class
class
ii
unclassifi
fusion
protein
prototyp
class
fusion
protein
influenza
ha
perhap
bestcharacter
fusion
intermedi
helic
coiledcoil
form
fragment
fusion
protein
repres
orthomyxo
paramyxo
retro
filo
structur
thought
repres
lowest
energi
state
reach
seri
conform
chang
induc
receptor
bind
low
ph
addit
format
coiledcoil
fusion
env
mani
virus
matur
proteolyt
cleavag
precursor
protein
yield
membraneanchor
subunit
contain
ntermin
fusion
peptid
coronavirus
includ
sarscov
cleav
remain
trimer
throughout
fusion
similar
fourstrand
coiledcoil
involv
number
intracellular
fusion
process
includ
synapt
vesicl
although
format
coiledcoil
irrevers
involv
revers
step
exampl
case
influenza
molecular
detail
pathway
lead
format
structur
fulli
understood
includ
sever
intermedi
distinguish
kinet
measur
structur
fig
molecular
dynam
simul
conform
transit
influenza
ha
induc
chang
neutral
low
ph
might
indic
complet
dissoci
globular
domain
ha
protein
could
expos
fusion
peptid
reorient
peptid
toward
target
membran
consist
springload
conformationalchang
class
ii
fusion
protein
proteolyt
cleav
intern
rather
ntermin
fusion
synthes
complex
second
membran
glycoprotein
activ
fusogen
potenti
class
ii
fusion
protein
involv
cleavag
accessori
protein
xray
crystallographi
three
class
ii
fusion
protein
e
protein
tbe
dengu
viru
protein
sfv
reveal
common
fold
protein
structur
unrel
class
viral
fusion
protein
class
ii
fusion
protein
fold
heterodim
companion
chaperon
glycoprotein
exampl
alphavirus
prm
pe
flavivirus
form
protein
network
viral
surfac
fusogen
conform
chang
lead
revers
dissoci
dimer
releas
monom
follow
irrevers
reassoci
stabl
homotrim
presenc
membran
fig
although
alphavirus
sfv
sin
requir
membran
compon
cholesterol
sphingolipid
bind
initi
conform
chang
flaviviru
tbe
requir
membran
compon
bind
target
membran
trimer
tbe
e
protein
might
involv
interact
unlik
class
class
ii
fusion
protein
conform
chang
g
protein
rabi
viru
vesicular
stomat
viru
vsv
famili
rhabdovirida
induc
low
ph
revers
indic
low
ph
trigger
transit
highenergi
intermedi
howev
interact
membran
could
induc
irrevers
conform
chang
vsv
rabi
viru
fuse
pure
lipid
vesicl
although
neither
viru
requir
specif
lipid
fusion
transit
equilibrium
state
entri
protein
could
provid
free
energi
overcom
membran
fusion
barrier
format
fusion
site
might
requir
mani
trimer
act
cooper
typic
estim
g
protein
rhabdovirus
sever
characterist
common
class
fusion
protein
exampl
intern
fusion
peptid
complex
protein
virion
surfac
class
ii
fusion
protein
exampl
cleav
heptad
sequenc
predict
coiledcoil
xray
crystal
structur
rhabdoviru
g
protein
solv
remain
seen
whether
becom
found
member
new
class
iii
fusion
protein
famili
envelop
virus
membran
fusion
import
role
conform
chang
class
fusion
protein
undergo
overcom
energi
barrier
enabl
membran
destabil
format
fusion
pore
energi
barrier
fusion
vsv
cell
estim
kcal
ref
proteinfre
model
lipid
bilay
activ
energi
compar
estim
valu
kcal
report
format
revers
first
intermedi
convers
second
semist
intermedi
irrevers
fusionpor
format
indic
basic
molecular
mechan
viral
fusion
might
involv
similar
lipid
molecular
rearrang
observ
fusion
model
lipid
membran
energi
releas
conform
chang
viral
protein
use
overcom
membran
fusion
energi
barrier
unclear
class
fusion
protein
recent
found
format
sixhelix
bundl
stabil
fusionpor
springload
conform
fig
requir
might
suffici
hamedi
fusion
transit
membran
fusion
pore
could
depend
part
subsequ
action
ha
fusion
peptid
transmembran
class
ii
fusion
protein
propos
phtrigger
conform
chang
result
insert
class
ii
protein
host
membran
turn
lead
fusionpor
seem
viral
protein
conform
chang
provid
suffici
energi
enabl
close
membran
apposit
less
nm
destabil
format
fusion
pore
proceed
intermedi
stalk
hemifus
diaphragm
might
common
known
viral
membran
fusion
data
obtain
baculoviru
consist
number
model
suggest
fusionpor
format
ensur
transfer
viral
nucleoprotein
complex
typic
stabl
solut
seem
intern
line
fusion
pore
must
hydrophil
fusionpor
format
requir
minim
number
oligomer
viral
entri
protein
form
supramolecular
complex
dynam
process
small
pore
open
close
revers
model
fusionpor
format
mainli
base
fusion
mediat
influenza
ha
might
prove
gener
valid
enlarg
fusion
pore
allow
transfer
genom
cell
occur
unknown
mechan
nonenvelop
virus
membran
penetr
mechan
penetr
nonenvelop
virus
remain
poorli
understood
although
rel
small
simpl
fusion
complex
envelop
virus
better
understood
owe
similar
envelop
virus
cell
surround
membran
fusion
necessarili
requir
signific
reorgan
viral
nucleoprotein
complex
contrast
either
whole
nonenvelop
viru
must
cross
membran
must
undergo
import
conform
chang
transfer
genom
membran
latter
case
energi
metast
state
must
use
destabil
cell
membran
also
reorgan
nucleoprotein
complex
genom
releas
destabil
membran
either
pore
structur
although
structur
sever
key
intermedi
conform
chang
viral
entri
protein
solv
atom
resolut
clear
great
deal
left
learn
owe
difficulti
associ
studi
rapid
conform
chang
molecul
virion
background
larg
number
surfac
molecul
virion
undergo
structur
chang
entri
protein
pathogenesi
viral
protein
destabil
plasma
endosom
membran
entri
also
destabil
membran
insid
cell
protein
close
proxim
suitabl
trigger
receptor
low
ph
low
calcium
concentr
exampl
condit
aris
transport
viral
protein
synthesi
host
cell
acid
golgi
vesicl
seem
virus
develop
strategi
cope
problem
exampl
g
protein
rhabdovirus
rabi
vsv
exist
nativ
activ
inact
conform
propos
inact
state
help
avoid
membran
fusion
transport
g
howev
env
induc
cell
lysi
interact
receptor
probabl
disrupt
import
intracellular
membran
method
cope
destabil
cell
function
signific
membran
fusion
effect
human
pathogenesi
unclear
perhap
virus
well
adapt
host
induc
signific
pathogen
effect
could
lead
reduct
viru
product
howev
virus
infect
new
host
hiv
sar
might
well
adapt
host
entri
protein
could
caus
cytopath
effect
cell
fusion
perhap
mediat
env
endogen
retrovirus
could
contribut
entri
inhibitor
antibodi
vaccin
entri
attract
target
inhibit
entri
machineri
extracellular
therefor
easier
drug
molecul
reach
intracellular
target
step
entri
process
target
entri
inhibitor
variou
type
molecul
protein
peptid
carbohydr
small
organ
molecul
nucleic
acid
supramolecular
structur
includ
liposom
phage
found
inhibit
entri
yet
antivir
two
entri
inhibitor
ref
approv
us
food
drug
administr
fda
clinic
use
exclud
human
immun
globulin
use
hepat
measl
virusspecif
polyclon
human
immun
globulin
use
cytomegaloviru
hepat
b
rabi
rsv
vaccinia
market
enfuvirtid
use
treatment
ongo
viral
infect
human
monoclon
antibodi
synagi
also
known
palivizumab
use
prevent
rsv
infect
neonat
immunocompromis
individu
small
molecul
regard
gold
standard
drug
peptid
taken
oral
small
organ
molecul
entri
inhibitor
pleconaril
show
promis
result
treatment
infect
caus
picornavirus
caus
common
approv
fda
owe
concern
potenti
interact
drug
although
differ
formul
present
evalu
use
lifethreaten
diseas
present
number
compound
clinic
trial
includ
small
organ
molecul
bind
coreceptor
entri
inhibitor
also
test
efficaci
microbicid
challeng
develop
viru
entri
inhibitor
major
problem
develop
effect
entri
inhibitor
includ
gener
viru
mutant
resist
drug
low
potenc
vivo
toxic
side
effect
although
problem
common
develop
antivir
cancer
drug
limit
efficaci
develop
entri
inhibitor
might
also
face
specif
challeng
virus
evolv
recogn
cellular
receptor
enter
cell
despit
presenc
host
immun
system
antibodi
exhibit
inhibitori
effect
viru
entri
must
bind
virus
alreadi
develop
number
strategi
immun
evas
includ
use
immunodomin
variabl
loop
incomplet
complementari
bind
surfac
oligomer
occlus
conform
multival
interact
problem
inher
design
inhibitor
especi
challeng
target
viru
entri
inhibit
highaffin
interact
small
molecul
anoth
strategi
use
virus
counteract
action
antibodi
entri
inhibitor
direct
celltocel
transmiss
virus
avoid
reduc
exposur
viru
inhibitor
design
penetr
membran
barrier
could
one
import
reason
low
efficaci
observ
vivo
otherwis
potent
vitro
inhibitor
low
inhibitor
potenc
combin
high
viru
mutat
rate
perhap
challeng
problem
develop
entri
inhibitor
although
rapid
progress
understand
structur
mechan
viru
entri
promis
new
approach
could
outsmart
viru
entri
inhibitor
treatment
protocol
clinic
use
far
develop
basi
predict
made
structur
model
main
sourc
new
inhibitor
still
screen
larg
librari
small
organ
molecul
natur
product
peptid
antibodi
howev
structur
entri
protein
invalu
develop
understand
mechan
inhibit
allow
improv
inhibitor
seem
like
sooner
later
structurebas
design
yield
entri
inhibitor
clinic
use
conserv
entri
intermedi
target
inhibitor
multival
inhibitor
approach
one
direct
research
could
hasten
arriv
entri
inhibitor
clinic
develop
compound
interact
conserv
intermedi
entri
process
protein
structur
bind
receptor
trigger
conform
chang
lead
format
entri
intermedi
typic
intermedi
transient
expos
virus
might
evolv
strategi
avoid
inhibitor
target
structur
addit
conserv
intermedi
usual
import
viru
entri
presum
easili
substitut
structur
mutat
exampl
success
design
entri
inhibitor
show
proof
concept
protein
interfer
conserv
intermedi
entri
ref
relat
exampl
class
peptid
could
broad
applic
sever
virus
contain
class
fusion
protein
peptid
deriv
region
fusion
protein
heptad
repeat
propens
form
coiledcoil
serv
fusion
intermedi
enabl
oligomer
protein
also
known
deriv
carboxytermin
heptad
region
show
potent
inhibitori
activ
similar
peptid
virus
includ
rsv
measl
viru
nipah
viru
hendra
viru
ebola
viru
sarscov
also
promis
entri
inhibitor
candid
howev
ebola
viru
inhibit
high
concentr
influenza
hamedi
fusion
inhibit
sarscov
infect
might
inhibit
either
k
bossart
c
broder
person
commun
perhap
owe
endocyt
entri
rout
virus
although
peptid
certain
promis
featur
includ
rel
small
size
might
ensur
good
penetr
combin
high
bind
affin
lack
oral
formul
short
halflif
possibl
toxic
immunogen
might
limit
applic
recent
small
molecul
identifi
inhibit
entri
broad
rang
isol
mechan
attribut
competit
receptor
bind
ref
howev
compound
inhibit
entri
one
isol
nm
bind
isol
nm
inhibitori
concentr
interfer
bind
indic
differ
inhibitori
mechan
analog
inhibitor
picornaviru
entri
pleconaril
might
inhibit
entri
bind
conserv
structur
import
conform
chang
must
undergo
viral
potent
virusspecif
inhibitor
viralmembranemerg
step
identifi
yet
anoth
promis
direct
develop
multival
inhibitor
overcom
problem
caus
mutat
viral
protein
escap
inhibit
multival
inhibitor
bind
sever
region
differ
protein
viral
surfac
one
exampl
multival
inhibitor
multimer
solubl
receptor
influenza
ref
potent
inhibitor
entri
vitro
extent
vivo
use
entri
inhibitor
combin
fusion
protein
could
also
result
increas
effici
final
improv
current
method
structurebas
design
account
protein
flexibl
dynam
bind
screen
method
would
certainli
expand
rang
possibl
inhibitor
test
neutral
antibodi
vaccin
immunogen
design
neutral
antibodi
usual
inhibit
viru
entri
prevent
attach
viru
cell
bind
entri
human
immunoglobulin
compos
concentr
antibodi
collect
pool
human
plasma
success
use
prevent
treatment
viru
infect
includ
rabi
hepat
b
measl
mump
varicella
cytomegaloviru
arenavirus
antibodi
complet
prevent
infect
infect
establish
much
less
effici
treatment
monoclon
antibodi
clinic
use
today
treat
viral
diseas
synagi
potent
polyclon
immunoglobulin
present
use
broadli
activ
numer
rsv
type
b
clinic
bind
f
protein
rsv
high
affin
nm
inhibit
viru
entri
cell
fusion
vitro
approxim
seem
efficaci
synagi
vivo
correl
high
affin
bind
potenc
antibodi
howev
synagi
measur
clinic
efficaci
administr
singl
mg
intraven
dose
infant
hospit
establish
rsv
infect
although
significantli
reduc
rsv
concentr
tracheal
xray
crystal
structur
indic
possibl
mechan
picornavirus
avoid
neutral
antibodi
mutat
nonconserv
amino
acid
residu
surround
receptorbind
site
nm
deep
nm
wide
canyon
fig
initi
hypothes
conserv
amino
acid
residu
canyon
access
antibodi
howev
later
shown
strongli
neutral
antibodi
penetr
deep
within
receptorbind
canyon
undergo
larg
conform
chang
without
induc
conform
chang
unusu
hypervari
residu
also
residu
framework
region
contact
canyon
yet
anoth
remark
mechan
immun
recognit
virus
recent
discov
receptor
mimicri
posttransl
modif
tyrosin
sulphat
antibodi
ref
huang
c
et
al
manuscript
prepar
seem
access
viral
surfac
recogn
antibodi
rapidli
mutat
virus
escap
neutral
antibodi
even
bind
structur
essenti
viru
replic
receptorbind
site
unless
bind
energet
ident
whether
viru
escap
neutral
antibodi
depend
interplay
antibodi
affin
avid
kinet
bind
gener
rate
concentr
viral
mutat
rate
fit
mutat
immunodomin
structur
loop
form
antibodybind
site
mutat
lead
chang
oligosaccharid
attach
viral
entri
protein
common
mechan
virus
avoid
mutat
conserv
residu
role
entri
mechan
typic
result
reduct
loss
infect
antibodi
deriv
bind
epitop
residu
contribut
bind
energi
could
potenti
entri
inhibitor
epitop
expos
viru
bind
receptor
typic
well
conserv
exampl
ref
epitop
one
potenti
problem
use
antibodi
entri
inhibitor
case
could
limit
access
postreceptorbind
state
viral
entri
protein
due
rel
larg
size
whole
antibodi
solv
problem
could
lead
develop
potent
broadli
neutral
antibodi
could
limit
gener
resist
virus
especi
inhibitor
use
combin
antibodi
inhibitori
molecul
mani
virus
especi
rna
virus
exist
swarm
virion
insid
infect
individu
might
significantli
differ
sequenc
isol
elicit
potent
broadli
neutral
antibodi
import
goal
vaccin
develop
potent
broadli
neutral
antibodi
env
exist
exampl
howev
elicit
antibodi
vivo
success
identif
broadli
neutral
antibodi
character
epitop
could
help
design
vaccin
immunogen
would
abl
elicit
neutral
antibodi
vivo
socal
present
vaccin
elicit
antibodi
entri
protein
develop
empir
use
antigen
rather
design
immunogen
basi
antibodi
produc
import
advantag
human
antibodi
therapeut
low
neglig
toxic
combin
high
potenc
long
halflif
howev
drawback
includ
gener
neutralizationresist
viru
mutant
limit
access
larg
antibodi
molecul
site
viru
replic
lack
oral
formul
high
cost
product
storag
viru
entri
physiolog
retarget
virus
usual
associ
diseas
howev
virus
benefici
human
endogen
retroviru
w
hervw
might
essenti
human
physiolog
format
placenta
hervw
env
known
syncytin
fusogen
role
human
trophoblast
cell
fusion
retrovir
particl
observ
placenta
along
fuse
placent
cell
morpholog
reminisc
viral
induc
syncytia
studi
led
propos
ancient
retrovir
infect
might
pivot
event
mammalian
virus
long
use
transfer
gene
cell
last
decad
anoth
import
applic
viral
deliveri
gene
drug
treat
cancer
major
challeng
develop
viru
entri
protein
deliv
molecul
specif
cell
high
effici
achiev
goal
often
desir
engin
virus
infect
cell
express
nativ
receptor
instead
target
cell
choic
engin
entri
protein
way
known
transduct
conceptu
simpl
approach
transduct
retarget
incorpor
protein
determin
cell
tropism
infect
virion
choic
known
viru
pseudotyp
use
retrovirus
adenovirus
requir
prior
knowledg
specif
interact
relat
approach
viral
entri
protein
use
produc
drug
gene
deliveri
vehicl
exampl
f
protein
sendai
viru
incorpor
liposom
form
l
protein
hepat
b
incorpor
yeastderiv
lipid
retarget
retrovirus
adenovirus
aav
achiev
conjug
entri
protein
molecular
adaptor
bispecif
antibodi
particular
receptorbind
properti
modif
entri
protein
normal
receptorbind
properti
abolish
ligand
altern
receptor
bind
incorpor
also
success
redirect
adenoviru
tropism
cell
cultur
unlik
work
entri
virus
requir
receptorinduc
conform
chang
retrovirus
unless
detail
molecular
mechan
conform
chang
better
understood
relat
approach
base
screen
librari
chimaer
env
differ
strain
random
peptid
insert
toler
site
viral
protein
approach
seem
promis
select
specif
retarget
vector
understand
structur
virus
could
help
improv
specif
effici
retarget
retarget
virus
complex
entri
mechan
involv
sever
protein
herp
virus
poxvirus
remain
challeng
challeng
perspect
elucid
molecular
mechan
dynam
conform
chang
drive
viru
entri
remain
signific
challeng
requir
develop
new
approach
studi
rapid
conform
chang
small
number
membraneinteract
protein
molecul
surround
mani
noninteract
molecul
realist
goal
determin
structur
protein
mediat
entri
human
virus
identif
cognat
cellular
receptor
research
continu
present
pace
goal
could
accomplish
within
next
decad
identif
cellular
receptor
human
virus
would
import
contribut
understand
viru
tropism
pathogenesi
variou
mani
case
unexpect
way
entri
protein
affect
pathogenesi
could
offer
new
opportun
intervent
ration
structuremechanismbas
design
entri
inhibitor
vaccin
immunogen
capabl
elicit
potent
broadli
neutral
antibodi
known
epitop
expect
contribut
toward
develop
clinic
use
therapeut
vaccin
develop
panel
human
monoclon
antibodi
everi
entryrel
protein
pathogen
human
virus
could
acceler
understand
entri
mechan
help
fight
viral
diseas
recent
progress
viru
retarget
also
rais
hope
possibl
design
entri
machin
deliv
gene
molecul
cell
choic
